Lee Chan Henry 4

What Happened

• Lee Chan Henry, SVP and General Counsel of BeOne Medicines (ONC), exercised several stock derivatives on July 22, 2026 and sold 1,669 American Depositary Shares (ADSs) in an open‑market transaction. He paid a total of $319,741 to acquire 1,669 ordinary-share equivalents from three option exercises (514 @ $194.47 = $99,958; 665 @ $213.32 = $141,858; 490 @ $159.03 = $77,925). The open‑market sale of 1,669 ADSs at $325.00 each generated proceeds of $542,425. The filing also reports conversions/exercises of additional derivative awards (6,682; 8,645; 6,370 shares) shown with $0 proceeds in the report.

Key Details

• Transaction date: July 22, 2026.
• Purchases (option exercises reported as Acquired): 514 @ $194.47, 665 @ $213.32, 490 @ $159.03 (total cash paid $319,741).
• Sale: 1,669 ADSs @ $325.00, proceeds $542,425; sale effected pursuant to a Rule 10b5-1 trading plan adopted May 29, 2026 (footnote F2).
• Several derivative exercises are reported as “Disposed” at $0 (6,682; 8,645; 6,370) — filing shows no cash proceeds for those items.
• Each ADS represents 13 ordinary shares (footnote F1); option/share counts and exercise prices are shown in ordinary‑share equivalents (F3).
• Vesting schedules for the reported awards are included in footnotes (F4–F6); unvested securities vest over four years and may accelerate on certain termination events.
• The Form 4 was filed on July 24, 2026 (within the typical 2‑business‑day reporting window).

Context

• For retail investors: this was a mixed activity day — the insider exercised options (an acquisition of shares) and then sold ADSs in the open market under a prearranged 10b5‑1 plan (a common method for orderly sales). Some exercises are reported with $0 proceeds in the filing; the Form 4 does not detail the mechanics (e.g., net settlement, withholding, or internal conversion) for those specific lines. These filings are factual disclosures of transactions and do not by themselves indicate the insider’s future view of the company.